BARRON’S MAGAZINE: The latest issue features…GLP-1s aren’t just for obesity anymore, and sales are exploding. Sizing up the winners.
Here Comes the Next Wave of GLP-1s. They’ll Treat a Lot More Than Obesity.
This blockbuster class of drugs is shattering all sales records. Which stock will do better—Eli Lilly or Novo Nordisk?
Nasdaq Records Worst July Since 2006
Despite Friday’s gains, the index wasn’t able to finish the month higher.
